argenx SE (ARGX) is listed on NASDAQ and operates in the Biotechnology industry (Healthcare sector).
argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Te...
| Rating | Analysts |
|---|---|
| Strong Buy | 1 |
| Buy | 30 |
| Hold | 5 |
| Sell | 0 |
| Strong Sell | 0 |
argenx SE is a biotechnology company focused on developing therapies for autoimmune diseases across the United States, Japan, Europe, the Middle East, Africa, and China. Its primary product candidate, efgartigimod, is being developed for conditions such as myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and several other autoimmune disorders. The company is also working on products like ENHANZE SC, Empasiprubart, and ARGX-119 for various neurological and inflammatory conditions. Additional research targets include ARGX-213, ARGX-121, ARGX-220, ARGX-109, and ARGX-118, focusing on immune system modulation and inflammation. argenx SE holds proprietary products such as VYVGART and VYVGART HYTRULO. The company collaborates with several partners, including AbbVie, Zai Lab, LEO Pharma, and Genmab, to advance therapeutic antibody development in immunology and oncology. It also has agreements with institutions like NYU Langone Health and Leiden University Medical Center. Founded in 2008, argenx SE is headquartered in Amsterdam, the Netherlands.
Over the last three fiscal years, the company has demonstrated a remarkable turnaround in its financial performance. Revenue consistently increased at an impressive CAGR of 84.3%, rising from $1.23 billion in 2023 to $4.16 billion in 2025. This growth was accompanied by a significant improvement in profitability, as the operating margin expanded by 58.0 percentage points, moving from -34.7% to 23.4%, and the net margin shifted from -24.1% to 31.1%. The company also achieved a notable earnings turnaround, with EPS increasing from -$5.16 to $19.63. Cash flow metrics showed a similar positive trajectory, with operating cash flow improving from -$420 million to $850 million, and free cash flow turning from -$464 million to $844 million, reflecting a robust FCF margin of 20.3% by 2025. Despite these gains, the company experienced a 15.5% increase in share count, which partially diluted per-share gains. Capital efficiency improved, as evidenced by a consistent increase in asset turnover to 0.56 and a significant reduction in capex intensity to 0.0015. The company's liquidity position remains strong, with a current ratio of 5.23 and a quick ratio of 4.87, while interest coverage improved dramatically to 237.5x, indicating a solid ability to meet interest obligations. Overall, the company's financial health has strengthened considerably, with a focus on scaling operations and enhancing profitability.
Recent developments for argenx SE (NASDAQ: ARGX) highlight significant institutional trading activity and analyst ratings. Mirae Asset Global Investments Co. Ltd. increased its holdings by 2,018 shares, valuing its position at $9,121,000. Wellington Management Group LLP notably expanded its stake by 324,653 shares, now holding 729,986 shares worth $538,408,000. Two Sigma Investments LP also increased its position by 250,278 shares, totaling 294,160 shares valued at $216,961,000. Conversely, Allspring Global Investments Holdings LLC reduced its stake by 38,598 shares. Analyst sentiment remains positive, with argenx receiving a consensus "Moderate Buy" recommendation. The average 12-month price target is set at $1,016, with Baird raising its target to $858, while Royal Bank of Canada adjusted its target to $925. Additionally, argenx showcased its neuromuscular leadership at AAN 2026, presenting new data supporting the broader use of VYVGART across myasthenia gravis (MG) and chronic inflammatory demyelinating polyneuropathy (CIDP). The Phase 3 ADAPT OCULUS study highlighted VYVGART's efficacy in MG patients, marking it as the first biologic treatment with such results. These developments underscore argenx's strategic focus on expanding its neuromuscular treatment pipeline while maintaining strong institutional interest and analyst support.